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Abstract Biotechnological and life science innovations
do not only lead to immense progress in diverse fields of
natural science and technical research and thereby drive
economic development, they also fundamentally affect the
relationship between nature, technology and society. Taken
this seriously, the ethical and societal assessment of
emerging biotechnologies as for example synthetic biology
is challenged not only to constrain on questions of bio-
safety and biosecurity but also to face the societal questions
within the different fields as an interface problem of sci-
ence and society. In order to map this vague and stirring
field, we propose the concept of bio-objects to explore the
reciprocal interaction at the interface of science and society
serious as well to have the opportunity to detect possible
junctions of societal discontent and unease before their
appearance.
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Synthetic biology seemed to be on the safe side. All
stakeholders’ statements—the European as well as the US
American—expose that ‘‘[…] no new regulations are
needed, but […] officials should be vigilant in case bigger
risks arise in the future’’ (Presidential Commission for the
study of Bioethical Issues 2010). Even more, the statement
of the German Research Foundation (DFG), Leopoldina
and Acatech, concludes that ‘‘with respect to biological
safety […] and the risk of misuse […] the existing legis-
lation in Germany is sufficient for the present state of
research’’ (Deutsche Forschungsgemeinschaft et al. 2009).
Simultaneously the Danish Council of Ethics as well as
The Danish Board of Technology assess that ‘‘synthetic
biology involves only limited risks in its present stage, and
there is currently no need for new legislation for this par-
ticular area’’ (The Danish Council of Ethics, The Danish
Board of Technology 2011). Of course it is necessary to
carefully survey the ongoing development due to the pos-
sible ethical as well as societal risks, but nevertheless there
are no general objections concerning ongoing research in
synthetic biology. Common to this scientific evaluation of
synthetic biology, all scientific statements tag the public at
large and its attitude towards synthetic biology in particular
as a crucial point. In sum, the story seems to require
awareness on a societal level, but due to the scientific
assessment nevertheless seems to be unproblematic overall.
Currently, the situation is changing: the supposedly
neutral or even positive societal perspective on and eval-
uation of synthetic biology is at risk. 111 civil society
organizations (CSO) call for a moratorium on synthetic
biology: ‘‘The Precautionary Principle must be applied to
synthetic biology because the risks of the technology are
inherently unpredictable with potentially far-reaching and
irreversible impacts’’ (Friends of the Earth U.S., Interna-
tional Center for Technology Assessment, ETC Group
2012). Due to such an argumentation the CSOs call for a
moratorium ‘‘on the release and commercial use of syn-
thetic organisms and their products’’ (Friends of the Earth
U.S., International Center for Technology Assessment,
ETC Group 2012). From a scientific perspective, the story
still remains clear: Nothing has changed! The researchers
are still working with microbes and bacteria, no accident
has happened up to now and biosafety as well as biose-
curity are still ensured. Nevertheless, synthetic biology
might no longer be restrained in the lab, it seeks to carve
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out and begins to ‘act’ in between science and society. The
different scientific, societal and economic actors are put in
a flurry: Will synthetic biology suffer the same fate as the
so called ‘green biotechnology’? How can this vague and
stirring field be mapped?
It perfectly fits the problem that heretofore there was no
detailed knowledge about which values and issues in
regard to synthetic biology can be found in the public and
which of those were relevant to what extent (Pauwels
2009). At the same time, the few studies that decidedly deal
with values and opinions state that the general public is
largely ignorant and unaware of what synthetic biology is.
Thus, the results of the latest Eurobarometer make clear
that 83 % of the Europeans have not noticed the topic of
synthetic biology yet and do not have any substantial ideas
about it (Gaskell et al. 2010). Studies from the USA show
that there has been some change in the perception of syn-
thetic biology: in 2010, 26 % of the interviewed people had
already heard about synthetic biology, whereas in 2008
only 9 % had done so (Hart Research Associates 2010).
With regard to the most important aspects addressing the
future development of synthetic biology 33 % believe that
the risks and benefits will be about equal (33 %), while
19 % think the benefits will outweigh the risks and 16 %
state the risks will exceed the benefits (Hart Research
Associates 2010). Such investigations that show a lack of
knowledge about synthetic biology present both opportu-
nities and risks. Opportunities arise due to the fact that the
lack of knowledge offers a possibility to inform society
seriously and risks arise in respect to the societal inability
to detect and uncover scandalization strategies by the sci-
ences, civil society organizations or the media.
Apart from these observations of a broad lack of
knowledge, there are descriptions of discontent that can be
detected not only in the terminology of the media but also
in the remarks of some scientists (Biotechnology and
Biological Sciences Research Council, Engineering and
Physical Sciences Research Council 2010). The described
discontent of the public accumulates to a fear of unknown
safety risks for one thing and to a general concern or
unspecified expectations concerning the implicit moral
consequences of synthetic biology itself for another thing
(Yearley 2009). Accordingly, Bedau et al. (2008) summa-
rize: ‘‘Thus, the prospect of artificial cells can be expected
to generate widespread unease, distrust and even hostility
in the public at large’’. This discontent is to a high extent
fueled by the fact that the promised applications of syn-
thetic biology are currently highly speculative visions
(Presidential Commission for the study of Bioethical Issues
2010).
In the current scientific debates, the prominent approach
dealing with the described discontent in the public is the
one that states that the public’s perception of synthetic
biology is generally linked to the extent of focus on
advantages and expected profits by the media and by
individual valuations: ‘‘The balance between potential risks
and benefits seems to be the basis for public confidence in
synthetic biology’’ (European Group on Ethics in Science
and New Technologies to the European Commission
2009). If this appraisal is put straight, the descriptions of
the rising discontent is endangered to be nothing more than
just marginal phenomena of an exaggerated vision that in
retrospect would be described as background noise due to
fulfilled expectations or falsified visions. Taken this
assumption seriously our exposed problem still remains:
How to explain the emerging discontent and intensive
reaction of society in general and the 111 CSOs in
particular?
The considerations so far emphasize that the societal
discontent has to be taken serious in order to map the
interface of science and society. As shown above, societal
discontent fulfills the function of an indicator for trans- and
reconfiguration of traditional and taken-for-granted-dis-
tinctions such as ‘living’ vs. ‘non-living’, ‘artificial’ vs.
‘natural’ or ‘subject’ vs. ‘object’. These distinctions have
hitherto been deemed as irrefutably valid on the level of
processing on the one hand and on the level of expressing
on the other hand. Here it is necessary to distinguish within
the societal discontent: On the one hand there is a kind
of more conscious—and therefore superficial—concern
which is mainly related to risk perceptions (or imagina-
tions) regarding the new technical procedures of synthetic
biology. On the other hand there is a kind of deeper and
subconscious unease that can be considered as an expres-
sion of taken-for-granted-assumptions. Regarding the first
differentiation (the level of procedure and biotechnology),
concerns concentrate on the new technical developments,
and thus it focuses on the continuous and discontinuous
classification of these technical procedures in comparison
to earlier procedures (Kelle 2009). Such a comparison—
coinciding with a strong reliance on a precautionary prin-
ciple—is always in danger of regarding a new development
extremely sceptically in a yet early stage. So as to deal with
this first differentiation of discontent, a focus on classical
questions of biosafety and biosecurity is necessary even if
it is not sufficient to discuss the function of discontent
thoroughly.
In order to grasp the full impact of the above mentioned
discontent it is necessary to consider the second differen-
tiation inscribed in the debates on biosafety and biosecu-
rity. It takes the form of a ‘‘deep grammar’’ (Wittgenstein
1922) which neither scientific nor public debates have so
far explicitly regarded and which has still been considered
only marginally by ethical research. Such a ‘‘deep gram-
mar’’ can be characterized as unease in regard to the dis-
ruption of previous taken-for-granted distinctions between
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‘living’ versus ‘non-living’ matter, ‘artificial’ versus
‘natural’ as well as ‘organic’ versus ‘non-organic’ (Ried
et al. 2011). Such an unease is triggered off by certain
branches of synthetic biology—especially research with
protocells—which could be able to create or claim the cre-
ation of epistemological and ontological entities that cross
out previous distinctions and dichotomies. This fact evokes
unease about which categories and terminologies to use
when describing these transformations adequately—both in
terms of science and in terms of life world’s language.
Taken seriously, both societal concern and unease as
obligatory parts of the societal discontent are not just
another additional ‘nice-to-have’ on the ‘ethical playlist’—
nevertheless to ensure the own crack of the (funding)
whip—but they rather draw concrete consequences for the
assessment of emerging biotechnologies as it can be eluci-
dated in the field of ‘plant-based synthetic biology’. Plant-
based synthetic biology aims at creating novel or optimal
production systems for bioactive metabolites and polypep-
tides. Considering an energy-efficient and CO2-efficient
production, approaches utilizing natural photosynthesis are
best suited (Biemelt et al. 2003). These light-driven pro-
cesses can also be used for the sustainable production of
anti-microbial peptides. Anti-microbial peptides have a
great potential as substitutes for conventional antibiotics
(Planson et al. 2011). There are two prerequisites for
developing next-generation antibiotics: identification or de
novo synthesis of bioactive polypeptides and the develop-
ment of optimal bioreactors for their production. Novel anti-
microbial peptides are either found in nature or designed by
in silico simulation studies (biased), molecular evolution
(unbiased), or by the construction of chimeric peptides
(combinatorial). Following the identification or the design
of novel bioactive polypeptides, synthetic genes promise to
allow efficient expression in target cells, which are created
and used for the generation of transgenic cells. Such target
cells may be higher plant-derived or algae-derived and by
processing and molecular engineering, optimal product
levels and security can be achieved. The production is not
limited to cells, but can be extended to genetically engi-
neered transgenic plants (Biemelt and Sonnewald 2004).
Against this backdrop, one expects this technology to be
at the frontier of modern medical research and industry—
but just the opposite is true. As proven by different com-
parative studies published by the EU, plants are—on a
theoretical level, potentially and relative to e.g. human
embryonic stem cells, animal models etc.—the most secure
and most cost-effective alternative when the production of
pharmaceutical-proteins is concerned (Spoek and Karner
2008; Goldstein and Thomas 2004; Ma et al. 2004). Nev-
ertheless, this promising approach is not applied in a
broader dimension, although there is no sufficient scientific
or technological reason not to use the achievements
attained by biotechnology. There is one leading reason for
this paradox: The point when the green light turns to red is
reached, when public perception and opinion—or in other
words: societal concern and unease—are considered. This
can be recently seen as the crucial point in the discussion—
initiated by the European Commission—about a possible
relaxation for the use of different products of the so called
‘green biotechnology’ in the field of nutrition (European
Commission 2011).
In sum, biotechnological and life science innovations do
not only lead to immense progress in diverse fields of
natural science and technical research and thereby drive
economic development; they also fundamentally affect the
relationship between nature, technology and society. What
can be done to frame this complex and perhaps chaotic
field and to develop strategies for dealing with these
challenges? In order to map this vague and stirring field,
we felt forced to think about and develop a tool which
firstly takes the reciprocal interaction at the interface of
science and society (especially the media driven society)
serious and secondly gives us the opportunity to detect
possible junctions of unease before they appear. Therefore,
we propose the concept of ‘bio-objects’. This term has been
recently proposed and is in need of further clarification and
conceptual work.
‘Bio-objects’ as a heuristic device to identify potential
conflicts at the interface of science and society
Against the background of the sketched current trends of
how science and society meet, ‘bio-objects’ are entities,
which can be characterized by three constitutively inter-
connected features:
1. They have been isolated from their natural contexts
(organs, individual cells and microorganisms, sub-
cellular structures) and subjected to further procedures
in order to be utilized in medical and life-science
contexts (Vermeulen et al. 2012).
2. Additionally, as products of scientific and technolog-
ical processes, ‘bio-objects’ share some characteristics
with organic structures and thus they seem to belong to
the realm of life. But as shown above, they differ
fundamentally from other organic entities (‘things’) in
the sense that they are also subjects of current—media
alerted—public debates, which affirmatively and/or
critically accompany the research process in the
form of an ethical, legal, social, medial and political
discourse.
3. A further attribute of ‘bio-objects’ is their potential for
economization, which is not limited to the monetization
or capitalization of ‘bio-objects’ themselves, but may
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also refer to the use of ‘bio-objects’ in value creation
processes more generally, even if this value cannot yet
be precisely quantified.
By using such a concept of ‘bio-objects’ we are able to
systematically line out and examine the interdependency of
these three dimensions concerning all ‘cutting edge bio-
technologies’. In concrete terms: the so characterized ‘bio-
objects’—not only products of synthetic biology, but also
hES or iPS cells-waver between being a scientific and
societal ‘benefit’ or ‘risk’.
Reformulating this point with Latour (1993), one of the
world’s most important protagonist in the field of science
and technology studies, ‘bio-objects’—though not explic-
itly entitling this concept—seem to take on a life on their
own and resist to be subsumed under the category of
‘things’. In their media presence and their provocation of
social discourse, products of synthetic biology, stem cells
or animal models themselves start acting and thus escape
the exclusive control and disposal of the actors who pro-
duce them. By developing such an ‘independent existence’,
they appear as subjects—or with others words: actants
(Latour 2007)—standing alongside classical actors, such as
scientists, politicians, patients, etc., in partly cooperative
and partly conflicting interactions.
Due to such a resistance of ‘bio-objects’ it is a current
‘‘matter of concern’’ (Latour 2008) that it is not yet clear
if they will be perceived as societal risk or benefit. Never-
theless, the outcome will be decisive for the public
perception and evaluation both of ‘bio-objects’ themselves
and of associated research processes like synthetic biology.
The intended and/or expected availability of ‘bio-objects’
for certain purposes—in the fields of medicine, energy
generation and storage, ecology, agriculture, food produc-
tion, etc.—will be constitutive for their public perception, for
the flow of financial resources for research and for the
attention of the media.
As shown above, it is all the more urgent to conduct a
thorough and timely interdisciplinary exploration of ‘bio-
objects’, in order to take up the described conceptual chal-
lenges. This holds true at least if science and politics wish to
identify adequate, sufficiently complex responses and feed
them into the public debate. Taken this seriously, it is also a
crucial point to scrutinize the ‘evolution’ of the ‘bio-objects’
concerning the interaction between the past and the currently
emerging ‘bio-objects’. Therefore, the modeling of this
cluster of problems between the poles of ‘nature’, ‘technol-
ogy’ and ‘society’ represents an urgent research goal, espe-
cially since a viable strategy for dealing with these
challenges and questions in advance has yet to be developed.
In order to identify, observe and meet these challenges,
we propose a three-dimensional matrix that will provide
orientation in the so far unexplored world of ‘bio-objects’
(Fig. 1).
The suggested model considers the multi-dimensionality
of ‘bio-objects’ and enables the integration of newly
appearing ‘bio-objects’, which is an obvious and essential
Fig. 1 Model to survey the
world of ‘bio-objects’. This
model illustrates the multi-
dimensionality of bio-objects.
Hereto the different dimensions
of domain (microorganism,
plant, animal and human), the
degree of complexity (sub-
cellular, cellular, tissue, and




application) are interlinked with
each other. Newly appearing
‘bio-objects’ can be placed in
this matrix (grey cuboid) and
this model enables to observe
and detect the transformation of
such ‘bio-objects’ trough
different dimensions
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goal posed by the dynamics in biotechnology as well as the
exposed societal challenges. The products of plant-based
synthetic biology, for example, can scientifically be limited
to the application fields of economy and drugs up to now.
But as the mentioned example demonstrates, ‘bio-objects’
start shifting through the various dimensions driven by the
scientific community, the media or civil-society-organiza-
tions. The proposed model enables to uncover the trans-
formation and the shift of ‘bio-objects’ through various
dimensions. Finally, this methodological approach allows a
retrospective as well as a prospective observation of
existing and upcoming ‘bio-objects’ in science, technology
and society. Such an prospective observation and under-
standing is a required necessity in order to deal with the
rising societal discontent.
An exploration of the subsequent governance chal-
lenges, however, presupposes the exact determination of
‘bio-objects’ with regard to their respectively associated
place within the matrix: Concerning synthetic biology it is
still completely open along which of the three dimensions
(domain, degree of complexity, societal application con-
text) ‘bio-objects’ will be discussed primarily, how they are
going to be received and evaluated by society and which
effects they will have on the protagonists themselves. In
relation to these urgent questions it is also still open wether
synthetic biology will be associated with the currently
neutral connoted ‘white biotechnology’ or the rather neg-
ative connoted ‘green biotechnology’. At this point, the
developed matrix provides the possibility to precisely
identify the different association possibilities of different
actors (scientists, CSOs, media, etc.), the possible disrup-
tions of previous distinctions as well as the combination of
both acts as a driver for different measurement possibili-
ties. Based on such an analysis of the possible path- and
crossways of the emerging ‘bio-objects’ it is also possible
to identify the potential links for a rising societal concern
and unease. To be sure, this obviously doesn’t mean that it
is possible to determine all crucial points but to calibrate
the up- and downstreaming waging between science,
technology and society more precisely (Nuffield Council
on Bioethics 2012). All this has to be noticed before a new
technology is brought into action. It is too late and (on a
societal level as well as economically) much too dangerous
to wait for the demand of a moratorium until the effec-
tiveness and resistance of ‘bio-objects’ at the interface of
science and society is taken seriously.
Therefore, the ethical and societal assessment of syn-
thetic biology is challenged not only to constrain on
questions of biosafety and biosecurity but also to face the
questions in synthetic biology as an interface problem of
science and society triggered by societal concerns and
unease. Furthermore, an interdisciplinary discussion on
‘bio-objects’ is among the most urgent desiderata of
scientific research in order to trace the emergence of ‘bio-
objects’ and the questions and conflicts evoked by them in
an adequate way. There will be no ‘exit’ if ‘white bio-
technology’ is to be developed successfully.
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